WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Clinical trials for WARM AUTOIMMUNE HEMOLYTIC ANEMIA explained in plain language.
Never miss a new study
Get alerted when new WARM AUTOIMMUNE HEMOLYTIC ANEMIA trials appear
Sign up with your email to follow new studies for WARM AUTOIMMUNE HEMOLYTIC ANEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug M281 aims to control rare blood disorder in phase 2/3 trial
Disease control OngoingThis study tests a drug called M281 in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The goal is to see if M281 can improve hemoglobin levels and reduce fatigue. About 118 participants will receive either M281 or a plac…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Phase: PHASE2, PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 06:26 UTC
-
Lifeline for anemia patients: drug access extended for those seeing benefits
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers ongoing access to the drug nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants must have completed 28 weeks of treatment and be experiencing clinical benefit, such as increas…
Matched conditions: WARM AUTOIMMUNE HEMOLYTIC ANEMIA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 04:37 UTC